1609545-83-6

Usage

Uses

Used in Pharmaceutical Applications:
(R)-4-(dibenzylamino)-3-fluoro-2-methylbutan-2-ol is used as an active pharmaceutical ingredient for its potential therapeutic properties. (R)-4-(dibenzylamino)-3-fluoro-2-methylbutan-2-ol's unique structure may allow it to interact with biological targets in novel ways, offering new avenues for the treatment of various diseases and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-4-(dibenzylamino)-3-fluoro-2-methylbutan-2-ol serves as a valuable building block or intermediate for the creation of more complex molecules. Its distinct structural features can be leveraged to synthesize a wide range of compounds with diverse applications, from pharmaceuticals to advanced materials.
Used in Chemical Research:
(R)-4-(dibenzylamino)-3-fluoro-2-methylbutan-2-ol is utilized as a research tool in chemical laboratories. Its unique properties and reactivity make it an interesting subject for studying various chemical reactions and mechanisms, potentially leading to new insights and discoveries in the field of chemistry.

Upstream product

• 75-16-1 methylmagnesium bromide 
• 88099-68-7 methyl (2R)-3-N,N-dibenzylamino-2-fluoropropanoate 
• 1193100-14-9 (R)-ethyl 3-(dibenzylamino)-2-fluoropropanoate 

Downstream Products

• 1544241-64-6 (3R)-4-amino-3-fluoro-2-methylbutan-2-ol 
• 1609545-78-9 (R)-tert-butyl (3-((bis(benzyloxy)phosphoryl)oxy)-2-fluoro-3-methylbutyl)carbamate 
• 1609545-79-0 (R)-4-amino-3-fluoro-2-methylbutan-2-yl dibenzyl phosphate 

Relevant academic research and scientific papers

Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis

IRAK4 is an attractive therapeutic target for the treatment of inflammatory conditions. Structure guided optimization of a nicotinamide series of inhibitors has been expanded to explore the IRAK4 front pocket. This has resulted in the identification of co

HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS

Disclosed are compounds of Formula (I) Formula(I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[l,2-b]pyridazin-3-yl, and pyrazolo[l,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; and R1, R3, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS

Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.